X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES UNICHEM LAB ALKEM LABORATORIES/
UNICHEM LAB
 
P/E (TTM) x - -273.6 - View Chart
P/BV x 6.8 2.0 334.7% View Chart
Dividend Yield % 0.6 1.3 50.6%  

Financials

 ALKEM LABORATORIES   UNICHEM LAB
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
UNICHEM LAB
Mar-17
ALKEM LABORATORIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,589320 496.7%   
Low Rs1,232221 557.5%   
Sales per share (Unadj.) Rs417.5167.2 249.7%  
Earnings per share (Unadj.) Rs56.312.0 470.7%  
Cash flow per share (Unadj.) Rs64.716.9 382.2%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.91.1 81.2%  
Book value per share (Unadj.) Rs292.9117.0 250.3%  
Shares outstanding (eoy) m119.5790.88 131.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.6 208.9%   
Avg P/E ratio x25.122.6 110.8%  
P/CF ratio (eoy) x21.816.0 136.5%  
Price / Book Value ratio x4.82.3 208.4%  
Dividend payout %22.625.1 89.9%   
Avg Mkt Cap Rs m168,65324,578 686.2%   
No. of employees `000NA5.2 0.0%   
Total wages/salary Rs m9,1712,487 368.7%   
Avg. sales/employee Rs ThNM2,928.3-  
Avg. wages/employee Rs ThNM479.4-  
Avg. net profit/employee Rs ThNM209.4-  
INCOME DATA
Net Sales Rs m49,91515,195 328.5%  
Other income Rs m1,645110 1,492.8%   
Total revenues Rs m51,56115,305 336.9%   
Gross profit Rs m8,4821,788 474.4%  
Depreciation Rs m1,006452 222.6%   
Interest Rs m67134 1,989.9%   
Profit before tax Rs m8,4511,413 598.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606326 492.9%   
Profit after tax Rs m6,7311,087 619.4%  
Gross profit margin %17.011.8 144.4%  
Effective tax rate %19.023.1 82.4%   
Net profit margin %13.57.2 188.5%  
BALANCE SHEET DATA
Current assets Rs m27,0626,426 421.1%   
Current liabilities Rs m15,3243,917 391.2%   
Net working cap to sales %23.516.5 142.4%  
Current ratio x1.81.6 107.7%  
Inventory Days Days6768 98.3%  
Debtors Days Days4177 53.6%  
Net fixed assets Rs m12,6107,410 170.2%   
Share capital Rs m239182 131.5%   
"Free" reserves Rs m34,49010,454 329.9%   
Net worth Rs m35,02710,636 329.3%   
Long term debt Rs m1,2124 27,536.4%   
Total assets Rs m54,38715,258 356.5%  
Interest coverage x13.642.9 31.7%   
Debt to equity ratio x00 8,361.7%  
Sales to assets ratio x0.91.0 92.2%   
Return on assets %13.67.3 185.3%  
Return on equity %19.210.2 188.1%  
Return on capital %24.913.6 182.9%  
Exports to sales %12.924.1 53.7%   
Imports to sales %3.14.9 62.4%   
Exports (fob) Rs m6,4613,666 176.3%   
Imports (cif) Rs m1,540752 204.9%   
Fx inflow Rs m6,5635,298 123.9%   
Fx outflow Rs m3,0120-   
Net fx Rs m3,5525,298 67.0%   
CASH FLOW
From Operations Rs m7,259683 1,062.1%  
From Investments Rs m1,864-1,316 -141.7%  
From Financial Activity Rs m-9,273592 -1,565.8%  
Net Cashflow Rs m-150-40 375.9%  

Share Holding

Indian Promoters % 66.9 50.1 133.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 15.1 219.2%  
FIIs % 0.0 3.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 31.7 -  
Shareholders   68,381 20,176 338.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  BIOCON LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jun 18, 2018 11:35 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - FRESENIUS KABI ONCO. COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS